睾酮替代疗法与前列腺癌风险
Testosterone replacement therapy and the risk of prostate cancer.
作者信息
Warburton Daniel, Hobaugh Christopher, Wang Grace, Lin Haocheng, Wang Run
机构信息
Division of Urology, University of Texas Medical School at Houston, Department of Urology; University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
出版信息
Asian J Androl. 2015 Nov-Dec;17(6):878-81; discussion 880. doi: 10.4103/1008-682X.150841.
Understanding the role of testosterone replacement therapy (TRT) in the development and progression of prostate cancer is an important concept in treating patients with symptoms of hypogonadism. This article revealed a small number of mostly retrospective, observational studies describing the use of TRT in the general population, in men with prostatic intraepithelial neoplasia (PIN), in men with a history of treated prostate cancer, and in men on active surveillance for prostate cancer. The current literature does not report a statistically significant increase in the development or progression of prostate cancer in men receiving testosterone replacement for symptomatic hypogonadism, and the prostate saturation theory provides a model explaining the basis for these results. The use of TRT in men with a history of prostate cancer is considered experimental, but future results from randomized controlled trials could lead to a change in our current treatment approach.
了解睾酮替代疗法（TRT）在前列腺癌发生和发展中的作用是治疗性腺功能减退症状患者的一个重要概念。本文揭示了少数主要为回顾性的观察性研究，这些研究描述了TRT在普通人群、患有前列腺上皮内瘤变（PIN）的男性、有前列腺癌治疗史的男性以及接受前列腺癌主动监测的男性中的应用。目前的文献并未报告接受睾酮替代治疗以缓解症状性性腺功能减退的男性前列腺癌发生或进展有统计学意义的增加，前列腺饱和理论提供了一个解释这些结果基础的模型。在有前列腺癌病史的男性中使用TRT被认为是试验性的，但随机对照试验的未来结果可能会导致我们当前治疗方法的改变。
Zotero 插件